Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

EMA-Compliant GLP ELISA for Quantifying Therapeutic Monoclonal Antibodies in Human Plasma

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

EMA-Compliant GLP ELISA for Quantifying Therapeutic Monoclonal Antibodies in Human Plasma

EMA-Compliant GxP ELISA for Therapeutic Monoclonal Antibody Quantification

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

Technical Question Franklin Biolabs GxP Protocol
What are the EMA’s core requirements for mAb ELISA validation? The European Medicines Agency (EMA) guideline on bioanalytical method validation requires demonstration of specificity, selectivity, accuracy, precision (repeatability and intermediate precision), and stability. Our validation protocols rigorously assess these parameters, including parallelism to confirm the standard curve is biologically comparable to the diluted study sample.
How do you manage matrix effects in human plasma samples? We mitigate matrix effects through systematic method development. This includes optimizing sample dilution factors, evaluating multiple blocking reagents, and selecting specific antibody pairs. All GxP validations are performed using a minimum of six unique lots of human plasma to ensure assay robustness across a diverse population.
What is the typical Lower Limit of Quantification (LLOQ) for a therapeutic mAb ELISA? The LLOQ is highly dependent on the antibody pair affinity and the specific therapeutic mAb. However, our platforms typically achieve LLOQs in the low ng/mL to high pg/mL range, providing the sensitivity required for terminal phase pharmacokinetic (PK) analysis and biodistribution studies.
How does Franklin Biolabs ensure data integrity for GxP-level assays? All GxP projects are executed within a 21 CFR Part 11 compliant framework. This includes the use of a validated Laboratory Information Management System (LIMS) for sample tracking, instrument software with secure audit trails, and independent Quality Assurance (QA) unit review of all data and reports.

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Executive Summary

Franklin Biolabs provides robust, EMA-compliant GxP ELISA services for the precise quantification of therapeutic monoclonal antibodies in human plasma. Our validated ligand binding assay framework generates the high-integrity pharmacokinetic data required for successful Investigational New Drug (IND) applications and other global regulatory submissions. We focus on mitigating matrix interference and ensuring assay performance meets stringent European regulatory expectations.

Pharmacokinetic Characterization for Biologic Therapeutics

Accurate pharmacokinetic profiling is fundamental to de-risking the development of biologic therapeutics. Quantifying the concentration of a therapeutic monoclonal antibody over time in a complex matrix like human plasma defines its absorption, distribution, metabolism, and excretion (ADME) profile. This data directly informs dose selection, safety assessments, and the overall clinical development strategy. Regulatory bodies, particularly the EMA, require comprehensive validation data to ensure the bioanalytical method is reliable and fit-for-purpose.

Our approach establishes a robust analytical foundation for your program. Within our >100,000 sq ft GxP-compliant facility, we develop and validate custom ELISAs tailored to your specific molecule. This meticulous bioanalytical work is an integral component of our programs, which have supported an 18-24 month average IND timeline, a metric reflecting the core team’s commitment to regulatory compliance and data quality, who have maintained a 100% IND success rate since 2019.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

A close-up shot of a modern bioreactor system and control unit from Pall Corporation in a clean laboratory environment.

Mitigating Anti-Drug Antibody (ADA) Interference

The potential for an immune response, resulting in the formation of anti-drug antibodies, is an inherent consideration for biologic therapeutics. Circulating ADAs can directly interfere with ligand-binding assays used for PK analysis. Specifically, ADAs can bind to the therapeutic mAb, masking the epitopes required for binding to the capture or detection antibodies in a sandwich ELISA format. This interference can lead to a significant underestimation of the drug concentration, compromising the integrity of the PK profile.

To address this, our method development strategy includes the evaluation and implementation of drug-tolerant PK assays. These assays often incorporate a sample pre-treatment step, such as acid dissociation, which disrupts the mAb-ADA immune complexes. This frees the therapeutic mAb, allowing for accurate measurement of the total drug concentration and providing a more reliable dataset to inform clinical decisions.

Assay Format Comparison for mAb Quantification

Selecting the appropriate ELISA format is a foundational step in method development. The choice impacts sensitivity, specificity, and workflow efficiency.

Assay Format Principle Advantages Considerations
Direct ELISA Target mAb is directly adsorbed to the plate and detected with a labeled primary antibody. Simple, fast workflow. Low sensitivity; high potential for background noise.
Indirect ELISA Target mAb is adsorbed to the plate, detected by an unlabeled primary Ab, then a labeled secondary Ab. Higher sensitivity than Direct ELISA; flexible. Cross-reactivity of the secondary antibody can be a factor.
Sandwich ELISA Target mAb is “sandwiched” between a capture antibody and a detection antibody. High specificity and sensitivity; suitable for complex samples. Requires a matched pair of antibodies that do not compete.

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

GxP-Compliant Data for European Regulatory Submissions

Our team specializes in developing and validating sandwich ELISAs, the gold standard for therapeutic mAb quantification in plasma. This format provides the specificity and sensitivity required to meet EMA expectations for bioanalysis. We ensure that the bioanalytical methods developed are robust and transferable for subsequent in vivo studies, providing consistent data generation from discovery through nonclinical development.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities